Setting the Record Straight on FDA Approvals in Oncology-Reply

Affiliations

¹ Division of General Internal Medicine, University of California-San Francisco, San Francisco.
² Department of Medicine, University of California-San Francisco, San Francisco.

Comment

Scott R Bauer et al. JAMA Intern Med. 2017.

. 2017 Aug 1;177(8):1223.

doi: 10.1001/jamainternmed.2017.2254.

¹ Division of General Internal Medicine, University of California-San Francisco, San Francisco.
² Department of Medicine, University of California-San Francisco, San Francisco.

No abstract available

Comment on

Quality of Life, Overall Survival, and Costs of Cancer Drugs Approved Based on Surrogate Endpoints.
Rupp T, Zuckerman D. Rupp T, et al. JAMA Intern Med. 2017 Feb 1;177(2):276-277. doi: 10.1001/jamainternmed.2016.7761. JAMA Intern Med. 2017. PMID: 27898978 No abstract available.
Setting the Record Straight on FDA Approvals in Oncology-Reply.
Zuckerman D. Zuckerman D. JAMA Intern Med. 2017 Aug 1;177(8):1222-1223. doi: 10.1001/jamainternmed.2017.2251. JAMA Intern Med. 2017. PMID: 28783833 No abstract available.